MICOTEF CREAM VAG 30G 2%+APPL

MICOTEF

active ingredients

MICOTEF 100 mg vaginal eggs A vaginal ovum contains: Active ingredient: miconazole nitrate 100 mg MICOTEF 2% vaginal cream 100 g vaginal ointment contain: Active ingredient: nitrate miconazole 2 g MICOTEF 400 mg vaginal capsules A vaginal capsule contains: Active ingredient: miconazole nitrate 400 mg

Excellent

MICOTEF 100 mg vaginal eggs: Solid semisynthetic glycerides. MICOTEF 2% vaginal cream: Butilidroxyanisolo, benzoic acid, oleic glyceride polyxyethylene, liquid paraffin, polyethyleneglycol palmito stearate, purified water. MICOTEF 400 mg vaginal capsules: Liquid paraffin, white vaseline, Labrafil 2130 BS, gelatin, glycerin, titanium dioxide, iron oxide, p-oxide sodium, p-oxide sodium of propile.

Therapeutic indications

Mycotic vulvo-vaginal infections (pure or mixed) and gram-positive bacteria (primitive or secondary).

Contraindications

Hypersensitivity to one of the components of the product.

Population

MICOTEF 100 mg vaginal eggs: Introduce in vagina 1 ovulum in the morning and 1 in the evening before bedtime, or according to medical judgment. The treatment must be continued for at least 15 days. We recommend the contemporary treatment of the partner with antifungal dermatological ointment. MICOTEF 2% vaginal cream: Deeply introduce into the vagina the content of the applicator (about 5 g of ointment) once a day, preferably the evening before bedtime. The treatment must be continued for at least 10-15 days, even after the disappearance of itching and leucorrea. MICOTEF 400 mg vaginal capsules: Introduce in the vagina a capsule, in the morning or in the evening before bedtime, or according to medical judgment. Treatment should be protracted for at least 4 days; in case of need to repeat the therapeutic cycle. We recommend the contemporary treatment of the partner with antifungal dermatological ointment.

Conservation

Store at a temperature not exceeding 25° C.

Warnings

Preparations for topical use, especially when used for prolonged treatment, can give rise to awareness phenomena. In these cases it is necessary to stop the treatment and establish suitable therapy. Keep out of reach of children.

Interactions

Miconazole, administered by systemic means, can increase the anticoagulant effect of cumarinic drugs: therefore, in case of contemporary use of MICOTEF and cumarinic drugs, it is necessary to determine with accuracy the anticoagulant effect of the latter, in order to reduce possibly the dose of cumarinic.

Effects

Some disorders such as burning and vaginal irritation, redness and itching, pelvic cramps and more rarely, headaches and skin rashes were reported. In these cases it is necessary to stop the treatment and establish suitable therapy.

Overdosing

No cases of poisoning or hyperdosage have been reported.

In pregnant women and during breastfeeding, the product should be administered in cases of actual need, under the direct control of the doctor.

Source: Farmadati